| T |
|
TAFI and diabetic nephropathy
|
| Kubisz P., Stasko J., Ivanková J., Holman B., Jeziková A., Galajda P. |
| |
|
TAFI antigen levels in local hemophilia A and vWD population
|
| Needham J., Knight S., Lewis H., Mainwaring C. J. |
| |
|
TAFI is cross-linked by its activation peptide to sites on fibrin(ogen) distinct from other inhibitors of fibrinolysis
|
| Mutch N. J., Moore N. R., Wang E., Booth N. A. |
| |
|
TAFI plasma levels are not increased in ischemic heart disease patients admitted to a coronary care unit
|
| Mannini L., Sofi F., Attanasio M., Fatini C., Sticchi E., Lari B., Abbate R., Prisco D., Gensini G. F. |
| |
|
Targeted expression of tissue factor pathway inhibitor and hirudin fusion proteins to endothelial cells reduces pathology in murine LPS-induced endotoxic shock – a novel model to study vascular inflammation
|
| Chen D., Mcvey J., Kemball-Cook G., Tuddenham E. G., Lechler R. I., Dorling A. |
| |
|
Targeting of the collagen binding site on glycoprotein VI is not essential for in vivo depletion of the receptor
|
| Schulte V., Rabie T., Prostredna M., Aktas B., Gruener S., Nieswandt B. |
| |
|
Tc-99 m labelled modified recombinant tissue plasminogen activator uptake in acute deep venous thrombosis
|
| Brighton T. A., Janssen J., Butler P. |
| |
|
Teicoplanin-dependent platelet antibodies as a cause of severe thrombocytopenia
|
| Campbell K., Garner S. F., Hurd C., Davidson S., Burman J., Treacy M., Smith G., Ouwehand W. H. |
| |
|
Temporal patterns and clinical outcomes in patients with heparin – induced thrombocytopenia
|
| Klein L., Galvez A., Klein O., Chediak J. |
| |
|
Temporary discontinuation of oral anti-coagulants in oncologic patients with mechanical heart valves
|
| Dobao M. L., Serro F., López M. A., Milheiro M. J., Carvalhais A. |
| |
|
Terminal intron splicing of the prothrombin premRNA is associated with 3'-cleavage site recognition and polyadenylation
|
| Meng X., Cui D., Murphy T. J., Howard T. E. |
| |
|
The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise
|
| Johe P., Østerud B. |
| |
|
The -148C/T variation in the human fibrinogen b promoter influences basal and IL-6 induced transcription and affects binding of nuclear proteins
|
| Verschuur M., De Jong M., Vos H. L., De Maat M. P. M. |
| |
|
The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR
|
| Medina P., Mira Y., Villa P., Estellés A., Vayá A., Navarro S., Ferrando F., Aznar J., Bertina R. M., Woodhams B., Migaud-Fressart M., España F. |
| |
|
The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene reduces the risk of venous thromboembolism in carriers of the factor V Leiden mutation
|
| Navarro S., Medina P., Vayá A., Estellés A., Villa P., Mira Y., Ferrando F., Aznar J., Bertina R. M., España F. |
| |
|
The 46C®T polymorphism in F12 gene is a risk factor for coronary artery disease
|
| Santamaría A., Martínez A., Tirado I., Oliver A., Vallve C., Souto J. C., Mateo J., Soria J. M., Fontcuberta J. |
| |
|
The 46C®T polymorphism in the F12 gene as a risk factor for venous thrombosis: association after linkage analysis
|
| Tirado I., Soria J. M., Mateo J., Oliver A., Souto J. C., Vallve C., Santamaria A., Borrell M., Fontcuberta J. |
| |
|
The 46C®T polymorphism in the F12 gene is a risk factor for ischemic stroke
|
| Santamaría A., Tirado I., Oliver A., Vallve C., Soria J. M., Martí-Fábrega J., Coll I., Felices R., Mateo J., Souto J. C., Fontcuberta J. |
| |
|
The activation of inflammation and coagulation by different heparin surfaces
|
| Johnell M., Larsson R., Siegbahn A. |
| |
|
The active conformations of Factor VIIa and Factor IXa: biochemical, biophysical, chemical and crystallographic studies
|
| Banner D. W., Mueller F., Brochon J. C., Huber W., Schoenfeld H. J., Sichler K., Kopetzki E., Benz J., Stihle M., Ackermann J., Groebke K., Alig L., Obst U., Tschopp T. |
| |
|
The administration of recombinant coagulation factor VIIa (rFVIIa) during neurosurgical procedures
|
| Gerlach R., Scharrer I., Raabe A., Seifert V. |
| |
|
The anti-angiogenic effect of endostatin is associated to a direct effect on the tumor growth in colon cancer
|
| Dkhissi F., Lu H., Soria C., Perricaudet M., Li H. |
| |
|
The antigenicity and immunogenicity of factor VIII
|
| Lollar P. |
| |
|
The antiphospholipid syndrome and cerebral manifestations
|
| Miesbach W., Gilzinger A., Pütz B., Asmelash G., Scharrer I. |
| |
|
The anti-platelet activity of J78 is mediated mainly by inhibition of arachidonic acid metabolism
|
| Yun Y., Jin Y., Ryu C., Park Y., Son D., Shin H., Cho M. |
| |
|
The anti-platelet effect of aspirin is reduced following administration of heparin during carotid endarterectomy
|
| Webster S., Jones C. I., Payne D. A., Hayes P. D., Sir Bell P. R. F., Naylor A. R., Goodall A. H. |
| |
|
The anti-thrombin variant -6Arg is a silent mutation
|
| Habart D., Fitches A., Olds R., Martinkova I., Hrachovinova I. |
| |
|
The Asp299Gly polymorphism of Toll-like receptor 4 as a genetic risk factor for acute coronary events
|
| Ameziane N., Beillat T., Verpillat P., Lamotte M., Seknadji P., Aumont M. C., Ollivier V., Lebret D., De Prost D. |
| |
|
The assessment of pretest probability in patients with suspected Deep-Vein Thrombosis is of great value in nonacademic teaching hospitals
|
| Tick L. W., Kramer M. H. H., Lobatto S., Huisman P. M., Stijnen P. J., Heul Van Der C., Huisman M. V. |
| |
|
The balance between the benefits and risks of treatment with vitamin K antagonists as perceived by patients
|
| Locadia M., Bossuyt P. M. M., Stalmeier P. F. M., Sprangers M. A. G., Bank I., Middeldorp S., Büller H. R., Prins M. H. |
| |
|
The bedside investigation of pulmonary embolism diagnosis (BIOPED) study- a triple blind randomized control trial comparing initial bedside diagnostic tests to standard care (initial V/Q scan) in the investigation of patients with suspected PE
|
| Rodger M. A., Jones G., Rasuli P., Raymond F., Clement A. M., Karovitch A., Djunaedi H., Makropoulos D., Bredeson C. N., Abbott- Howley H., Wells P. S. |
| |
|
The biphasic waveform of APTT optical clot formation profile is related with the activation of FVII but not with ISTH DIC score or classical coagulation activation parameters
|
| Cauchie P., Zouaoui Boudjeltia K., Carlier E., Fourdrain A., Deschepper N., Migaud-Fressart M., Brohée D. |
| |
|
The bradykinin B2 Receptor knockout mouse is protected from thrombosis
|
| Schmaier A. |
| |
|
The C1 domain substitution His2155Asp severely reduces factor VIII binding to von Willebrand factor
|
| Habart D., Jacquemin M., LAVEND'Homme R., Novotny M., Vorlova Z. |
| |
|
The calibrated Thrombogram: exact monitoring of thrombin generation in clotting platelet rich- and platelet poor plasma
|
| Giesen P., Al Dieri R., Wagenvoord R., Nijhuis S., Béguin S., Hemker H. C. |
| |
|
The carboxypeptidase mediated down-regulation of fibrinolysis exhibits a threshold effect which is masked by the intrinsic instability of TAFIa
|
| Walker J. B., Bajzar L. |
| |
|
The catalytic subunit of pseutarin C, a group C prothrombin activator from Pseudonaja textilis is structurally similar to blood coagulation factor X
|
| Rao V. S., Swarup S., Kini R. M. |
| |
|
The CAVA study: a double-blind randomized controlled trial of clopidogrel and aspirin vs. aspirin alone in patients with intermittent claudication undergoing peripheral percutaneous transluminal angioplasty
|
| Cassar K., Ford I., Greaves M., Brittenden J., Bachoo P. |
| |
|
The central effects of fivefold injections of unfractionary heparin in small doses
|
| Kondashevskaya M., Kondashevskaya M. V. |
| |
|
The choice of assay, agonist and anticoagulant for determining efficacy of GPIIb/IIIa antagonists
|
| Dooley M., Fitzgerald D., Cox D. |
| |
|
The choice of tubes for blood collection – a plastic tube is not enough
|
| Ramström S., Lindahl T. L. |
| |
|
The clinical outcome of pediatric venous thrombo-embolic disease in one tertiary centre
|
| Van Ommen C. H., Heijboer H., Hutten B. A., Peters M. |
| |
|
The clinical relevance of anti-b2-GP1 antibodies assays in the presence of antiphospholipid antibodies and/or lupus anticoagulant
|
| Li R., Ocmant A., Collard C., Vissac A. M., Amiral J., Wijns W. |
| |
|
The clinical significance of TpP in patient with acute coronary syndrome
|
| Zhimin Z., Jun C., Xiaodong H. |
| |
|
The combination of lupus anticoagulant sensitive and insensitive aPTT reagent together with dRVVT screening reagent for the exclusion of the presence of lupus anticoagulant
|
| Coen D., Zadro R. |
| |
|
The contribution of inherited thrombophilic risk factors to venous thromboembolism (VTE) in patients with systemic lupus erythematosus (SLE)
|
| Brouwer J. L. P., Bijl M., Kluin-Nelemans J. C., Van Der Meer J. |
| |
|
The control of von Willebrand Factor multimer size by thrombospondin-1
|
| Pimanda J., Kershaw G., Lawler J., Chesterman C., Hogg P. |
| |
|
The coordinated transcription of genes encoding regulators of cell cycle progression revealed by expression profiling upon calcium ionophore A23187 treatment of B lymphoblasts from a patient with Scott syndrome
|
| Kozian D., Nitsche A., Martinez M. C., Galitzine M., Proulle V., Schumann B., Freyssinet J. M., Herrmann M., Meyer D., Kerbiriou-Nabias D. |
| |
|
The CRP-VLDL complex, a predictor and marker of DIC, exists in vivo
|
| Marshall N. J., Downey C., Toh C. H. |
| |
|
The C-terminus of a 2-anti-plasmin: effect on fibrinolysis
|
| Thomas L., Mutch N. J., Moore N. R., Booth N. A. |
| |
|
The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia
|
| Sharma L., Melis E., Hickey M. J., Clyne C. D., Davenport P, Erlich J., Morand E., Carmeliet P., Tipping P. G. |
| |
|
The cytoplasmic domain of tissue factor plays an important role in innate and adaptive immunity
|
| Sharma L., Hickey M. J., Melis E., Carlin K., Carmeliet P., Tipping P. G. |
| |
|
The development and evaluation of a quality of life questionnaire for children with hemophilia
|
| Robben W., Plug I., De Goede-Bolder A., Peters M., Rosendaal F. R., Koopman H. M. |
| |
|
The development of an automated, real time, oral anticoagulant dosing module to enhance traditional computerized decision support software (CDSS)
|
| Baker P., Davidson S. R., Sharp P., Keeling D. M. |
| |
|
The development of inhibitors directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A
|
| Von Auer C., Oldenburg J., Auerswald G., Von Depka- Prodzinski M., Eifrig B., Escuriola-Ettinghausen C., Heinrichs C., Klamroth R., Kreuz W., Kurnik K., Lenk H., Pollmann H., Siegmund B., Syrbe G., Varvenne M., Wolf H. H., Zimmermann R., Scharrer I. |
| |
|
The development of pro-hemostatic lyophilized platelets with minimized risk for intravascular coagulation
|
| Fischer T. H., Russell K. E., Merricks E. P., Nichols T. C., Bode A. P. |
| |
|
The effect of b-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism
|
| Schönauer V., Giannini S., Christ G., Quehenberger P., Bieglmayer C., Stain M., Kyrle P. A., Weltermann A. |
| |
|
The effect of ABO and Secretor genotypes on thrombin generation
|
| Clark P., Comrie A., Wilson S., Walker I.D., Greer I.A., O'Sullivan A. |
| |
|
The effect of age on plasmin generation in the presence of fibrin monomer on endothelium
|
| Parmar N., Mitchell L. G., Berry L. R., Chan A. K. C. |
| |
|
The effect of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, on the prolongation of aPTT and ECT in orthopedic patients: a population pharmacodynamic study
|
| Stangier J., Liesenfeld K. H., Troconiz Ch., Tillmann I. F., Schaefer H. G., Hermansson K., Eriksson B. I. |
| |
|
The effect of clopidogrel on walking distance and hemostasis in patients with intermittent claudication
|
| Komarov A., Kropacheva E., Tarasova T., Titaeva E., Dobrovolksy A., Panchenko E., Matveeva M. |
| |
|
The effect of dietary vitamin K1 on warfarin maintenance dose requirements
|
| Weibert R., Nguyen T., Adler D. |
| |
|
The effect of direct FXa inhibitor and direct thrombin inhibitor on TF induced DIC and venous thrombosis models in anesthetized rat – thrombin inhibitor enhance the platelet consumption in DIC model
|
| Furugohri T., Shiozaki Y., Muramatsu S., Honda Y., Matsumoto C., Isobe K., Sugiyama N. |
| |
|
The effect of drotrecogin alfa (Xigris) on the biphasic PTT waveform in patients with sepsis
|
| Van Cott E.*, Smith E.Y. †, Charles L.A.†, Laposata M.†, Dew R.B.† |
| |
|
The effect of factor XIII Val34Leu on clot structure is fibrinogen dependent: evidence for a mechanism for cardioprotection of the Leu allele at high fibrinogen levels
|
| Lim B. C. B., Ariens R. A. S., Carter A. M., Weisel J. W., Grant P. J. |
| |
|
The effect of low and high dose aspirin on the expression of monocyte tissue factor
|
| Wilson E., Mccoll M. D., Pearson C., Greer I. A., Walker I. D. |
| |
|
The effect of orally administered heparins on a rat carotid arterial model of thrombosis
|
| Hiebert L. M., Pinel C., Wice S. M. |
| |
|
The effect of oxidized low-density lipoprotein on the activation of platelets
|
| Korporaal J. A., Gorter G., Van Rijn H. J. M., Akkerman J. W. N. |
| |
|
The effect of pathogen inactivation treatment processes on VWF cleaving protease, VWF:Ag and protein S levels in blood components used in therapeutic plasma exchange for thrombotic thrombocytopenic purpura
|
| Yarranton H., Lawrie A. L., Purdy G., Mackie I. J., Machin S. J. |
| |
|
The effect of peroxisome proliferator-activated receptor a and g activators on lipopolysaccharide-induced monocyte tissue factor activity and TNFa in human whole blood
|
| Eilertsen K., Østerud B. |
| |
|
The effect of pretreatment with clopidogrel on platelet and coagulation activation in patients with stable angina undergoing elective coronary stenting
|
| Weltermann A., Fritsch P., Kyrle P. A., Schoenauer V., Christ G., Huber K. |
| |
|
The effect of refined and red palm olein compared to sunflower oil on lipids and homeostatic factors in hyperfibrinogenemic patients
|
| Scholtz S. C., Pieters M., Oosthuizen W., Bosman M. J. C., Jerling J. C., Rutengwe R. M., Vorster H. H. |
| |
|
The effect of selective serotonin reuptake inhibitor anti-depressants on platelets
|
| Maurer-Spurej E., Pittendreigh C. |
| |
|
The effect of temperature and pH on the activity of FVIIa: implications for the efficacy of high-dose FVIIa in hypothermic and acidotic patients
|
| Hoffman M., Meng Z. H., Wolberg A. S., Monroe D. M. |
| |
|
The effect of thyrotropine releasing hormone on blood coagulation
|
| Grigorjeva M., Golubeva M. |
| |
|
The effect of two novel plastic citrate tubes (BD Vacutainer Plus): Results in normal subjects and subjects undergoing Unfractionated heparin therapy
|
| Bowyer A. E., Kitchen S., Pastorelli D., Makris M. |
| |
|
The effects of folic acid supplements on coagulation status in pregnancy
|
| Deol P., Barnes T., Dampier K., Mitchell V., Pasi K. J., Oppenheimer C., Pavord S. R. |
| |
|
The effects of thalidomide analogues on VEGF and IL-6 production in myeloma and endothelial cell cocultures
|
| Molostvov G., Morris A., Rose P., Basu S. |
| |
|
The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke
|
| Zhao L., Fletcher S., Weaver C., Leonardi-Bee J., May J., Fox S., Heptinstall S., Bath P. |
| |
|
The efficacy of standard dose vs. 30 mL kg-1 FFP in correcting laboratory parameters of hemostasis in critically ill patients
|
| Collins P., Chowdhury P., Saayman A. G., Paulus U., Hathaway L., Findlay G. |
| |
|
The endothelial expression of pai-1 by Angiotensin II is dependent on the 4 g/5 g polymorphism: clinical and therapeutic implications
|
| Roncal C., Orbe J., Monasterio A., Belzunce M., Páramo J. A. |
| |
|
The epidemiology of coagulation variables in coronary artery disease
|
| Danesh J. |
| |
|
The epidemiology of venous thromboembolism in California
|
| White R., Romano P. S., Zhou H. |
| |
|
The epidemiology of venous thrombosis
|
| Cushman M. |
| |
|
The epitope of the CD109 monoclonal antibody 8A3 overlaps with the epitope of Gov antibodies: implications for Gov antibody detection
|
| Smith G., Joutsi-Korhonen L., Haas De M., Berry J., Campbell K., Garner S., Schuh A., Watkins N., Ouwehand W. H. |
| |
|
The experience of treatment of children with hemostasis system pathology treatment with recombinant factor VII NovoSeven
|
| Vdovin V. V., Svirin P. V., Shiller E. E., Plahuta T. G., Larina L. E., Yakunina L. N., Soskov G. I. |
| |
|
The Factor V HR2 haplotype and the risk of venous thrombosis: a metanalysis
|
| Castaman G., Faioni E. M., Tosetto A., Bernardi F. |
| |
|
The factor V Leiden mutation results in the in vivo loss of a critical FV anticoagulant function
|
| Westrick R. J., Sun H., Eitzman D. T., Manning S. L., Yang A. Y., Siemieniak D. R., Ayigari A., Ginsburg D. |
| |
|
The factor V R2 allele (A4070G), factor V gene G1628A mutation, factor V Hong Kong (A1090G), factor V Cambridge (G1091C), the tissue factor pathway inhibitor gene C536T mutation and the risk of venous thrombosis in Thai patients
|
| Angchaisuksiri P., Inkaew B., Busabaratana M., Aryuchai K., Thanyachai S., Atichartakarn V. |
| |
|
The financial burden of VTE: Arixtra a cost-saving option
|
| Kwong L. |
| |
|
The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C
|
| Yang L., Rezaie A. R. |
| |
|
The frequencies of fibrinogen polymorphisms Taq I, Hae III and Bcl I in patients with deep-vein thrombosis
|
| Bozic M., Teran N., Peterlin B., Stegnar M. |
| |
|
The frequency of P475S polymorphism in von Willebrand factor-cleaving protease among Chinese population and its relevance to arterial thrombotic disorders
|
| Gao W. Q., Wang Z. Y., Bai X., Ruan C. |
| |
|
The functional profiles of circulating T lymphocytes distinguishes patients with stable angina and unstable angina
|
| Higashitani M., Murasaki K., Tatsumi F., Ueno A., Murasaki S., Haruta S., Kawana M., Tanoue K., Kasanuki H. |
| |
|
The functional self association of von Willebrand factor is modulated by a multiple domain interaction
|
| Ulrichts H., Vanhoorelbeke K., Vauterin S., Deckmyn H. |
| |
|
The FV Leiden, FII G20210A and MTHFR C677T mutations in healthy and thrombophilic Yugoslav population
|
| Djordjevic V., Rakicevic LJ., Mikovic D., Kovac M., Radojkovic D., Savic A. |
| |
|
The G allele of IL-6–174G/C polymorphism is a risk factor for restenosis after coronary stent implantation by increased inflammation and platelet activation
|
| Kottmann T., Piper C., Farr M., Wiemer M., Baller D., Kleesiek K., Horstkotte D. |
| |
|
The G>T point mutation (Val34Leu) in the Factor XIII-A subunit gene in venous leg ulcers
|
| Gemmati D., Tognazzo S., Serino M. L., Fogato L., Carandina S., De Palma M., Izzo M., Moratelli S., Ongaro A., De Mattei M., Caruso A., Mari R., Liboni A., Scapoli G. L., Zamboni P. |
| |
|
The G>T point mutation in codon 34 of the factor XIII gene and the risk of pre-eclampsia
|
| Clark P., Freeman D. J., Streja E., Sattar N., Walker I. D., Greer I. A. |
| |
|
The Gas6 receptors Axl, Sky, and Mer function to enhance human platelet degranulation and aggregation
|
| Perrin L. A., Gould W. R., Baxi S. M., Peterson J. T., Leadley R. |
| |
|
The genetics of type 1 vWD
|
| Rodeghiero F. |
| |
|
The German thrombophilia-registry – first results: Women specific risk factors and venous thrombosis
|
| Lindhoff-Last E., Klaeffling C., Luxembourg B., Erbe M., Gerdsen F., Schindewolf M., Kirchmayr K., Bauersachs R., Dick A., Spannagl M. |
| |
|
The Gs agonist PACAP(1–38) is a physiological inhibitor of platelet aggregation and megakaryocyte maturation
|
| Freson K., Wittevrongel C., Thys C., Vermylen J., Hoylaerts M., Van Geet C. |
| |
|
The hemostatic balance between tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in cultures of human primary trophoblasts
|
| Aharon A., Brenner B., Tennenbaum G., Lanir N. |
| |
|
The hemostatic effectiveness of regular infusions of factor VIII concentrates in hemophilia A patients with high responder inhibitors
|
| Kasuda S., Tanaka I., Shima M., Tanaka M., Matsumoto T., Fukuda K., Sakurai Y., Nishiya K., Giles A. R., Hatake K., Yoshioka A. |
| |
|
The high frequency and specificity of the Lupus cofactor effect in a dPT screen
|
| Dlott J. S., Taylor J. M., Dixon J. L., Willen D. R., Triplett D. A. |
| |
|
The homocysteine, PAI-1 and tPA concentration ratio status: a thrombogenic link in classic homocystinuria
|
| Castaneda S., Arbelaez L. F., Cordoba A. |
| |
|
The human protein C gene promoter is regulated by androgenic but not oestrogenic factors
|
| Andia A., Spray J. R. K., Winship P. R. |
| |
|
The impact of factor V Leiden on the endothelial cytokine response to coagulation activation modulated by drotrecogin alfa (activated)
|
| Liebe V., Brückmann M., Wirmer S., Hoffmann U., Schellinger S., Borggrefe M., Haase K. K., Huhle G. |
| |
|
The impact of GPIIb-IIIa and GPIa-IIa polymorphisms on the adhesion of platelets to collagen and fibrinogen in a microtiter-plate adhesion system under static and dynamic conditions
|
| Carlsson L. E., Grossjohann B., Freier J., Santoso S., Greinacher A. |
| |
|
The impact of interassay-variations in the International Normalized Ratio on dosing oral anti-coagulants
|
| Piso B., Quehenberger P., Krinninger B., Handler S., Watzke H. |
| |
|
The impact of intravenous heparin administration on duration of hospitalization
|
| Dunn A., Capasso M., Beran M., Bioh D., Siu A. |
| |
|
The impact of thromboembolism
|
| Tapson V. |
| |
|
The importance of repeat laboratory testing in the diagnosis of heparin-induced thrombocytopenia
|
| Francis J., Drexler A. |
| |
|
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study
|
| Girolami B., Prandoni P., Stefani P. M., Tanduo C., Sabbion P., Eichler P., Ramon R., Baggio G., Fabris F., Girolami A. |
| |
|
The incidence of recurrent thrombotic events in fertile women with acute venous thromboembolism: a prospective cohort study
|
|
| |
|
The incidence of venous thromboembolism in carriers of single identified prothrombin G20210A: a retrospective cohort study
|
| Simioni P., Zerbinati P., Luni S., Fadin M., Gavasso S., Tognin G., Prandoni P., Girolami A., Tormene D. |
| |
|
The incidence of venous thromboembolism in double-heterozygous carriers of antithrombin, protein C and protein S deficiency and HR2 haplotype
|
| Tormene D., Simioni P., Fortuna S., Zerbinati P., Tognin G., Prandoni P., Girolami A. |
| |
|
The incidence of venous thromboembolism in homozygous or double heterozygous carriers of the factor V Leiden mutation, prothrombin 20210 A mutation and HR2 aplotype: interim report
|
| Tormene D., Simioni P., Luni S., Zerbinati P., Fadin M., Gavasso S., Tognin G., Prandoni P., Girolami A. |
| |
|
The influence of change of cell surfaces on aggregation function of blood
|
| Mirsamatova G. |
| |
|
The influence of cyclooxygenase-2-selective nonsteroid anti-inflammatory drugs on bleeding complications in aspirin users
|
| Korzh I., Fedotova I., Nemtsova V., Korzh O. |
| |
|
The influence of exercise and stress on markers of activation of coagulation and fibrinolysis in young postinfarction patients
|
| Vitsenya M., Titaeva E., Shubina T., Dobrovolsky A. |
| |
|
The influence of metformin on markers of inflammation in subjects with type 2 diabetes mellitus: evidence to support the common soil hypothesis
|
| Carter A. M., Bostock J. A., Bennett C. E., Boothby M., Grant P. J. |
| |
|
The influence of Percutaneous Transluminal Coronary Angioplasty (PCTA) in patients with stable angina on the inflammation markers, lymphocyte activation and platelet-leukocyte aggregates in peripheral venous blood
|
| Czyz A., Kolacz E., Angerer D., Zawilska K. |
| |
|
The influence of the prothrombin mutation 20210 GA and the level of prothrombin on the thrombin generation
|
| Siegemund A., Siegemund T., Petros S., Scholz U., Engelmann L. |
| |
|
The influence of the substitution of arginine within the RGD tripeptide motif of dendroaspin on its activity as a potent inhibitor of platelet aggregation and cell adhesion
|
| Lu X., Wattam B., Davies J., Lu D., Shang D., Sun Y., Rahman S., Scully M., Kakkar V. |
| |
|
The influence of tissue factor (CD142) on endothelial cell apoptosis and proliferation
|
| Pradier A., James N. J., Bruckdorfer K. R., Ettelaie C. |
| |
|
The influence of treatment with low molecular weight heparins (dalteparin, nadroparin) on the clinical course and hemostasis activation markers in patients with unstable angina
|
| Ryabysh E., Shubina T., Titaeva E., Dobrovolsky A., Staroverov I. |
| |
|
The influence of warfarin on plasma levels of soluble tissue factor, prothrombin fragment 1 + 2 and D-dimer in patients after acute myocardial infarction
|
| Arnesen H., Hurlen M., Seljeflot I. |
| |
|
The inhibitory action of quercetin on GPVI-mediated platelet signaling and activation
|
| Hubbard G., Stevens J. M., Sage T., Jordan P. A., Lovegrove J. L., Gibbins J. M. |
| |
|
The interaction of the 268–282 region of GpIba with the heparin binding site of thrombin inhibits the enzyme activation of Factor VIII
|
| De Cristofaro R., De Filippis V. |
| |
|
The interaction of von Willebrand factor with GPIba; induces GPIIb-IIIa-dependent secretion
|
| Auger J., Marshall S. J., Harrison P., Salmon G., Watson S. P. |
| |
|
The irrelevance of International Normalized Ratio in the monitoring of anti-IIa and anti-Xa drugs
|
| Tobu M., Demir M., Iqbal O., Lietz H., Hoppensteadt D., Walenga J., Fareed J. |
| |
|
The Jarvik 2000 artificial heart does not affect the activation status of platelets
|
| Loeffler C., Schwarz M., Martin J., Siegenthaler M. P., Bassler N., Beyersdorf F., Bode C., Peter K. |
| |
|
The laboratory evaluation of aspirin-resistance in normal, healthy subjects
|
| Kunicki T. J., Salomon D. R., Nakagawa P., Crisler P., Nugent D. J. |
| |
|
The long-term analytical performance of assay of anti-thrombin, protein C and protein
|
| Meijer P., Haverkate F., De Maat M. P. M., Kluft C. |
| |
|
The long-term clinical course of acute deep vein thrombosis of the arm: a prospective cohort study
|
| Prandoni P., Bernardi E., Marchiori A., Frulla M., Concolato A., Piccioli A., Simioni P., Lensing A. W. A., Prins M. H., Girolami A. |
| |
|
The low frequency allele of glycoprotein VI raises the threshold for platelet activation by collagen and collagen-related peptides
|
| Joutsi-Korhonen L., Smethurst P. A., Rankin A., Gray E., Ijsseldijk M. J. W., Onley C. M., Watkins N. A., Williamson L. M., Goodall A. H., De Groot P. G., Farndale R. W., Ouwehand W. H. |
| |
|
The mannometric profile of native arteriovenous fistulas in the Avicenne Hemodialysis Center of Casablanca (preliminary results)
|
| Sabik K, Taouaf A., Atlassi H., Mseffer Y., Zamd M., Ramdani B., Zaid D. |
| |
|
The MATISSE-DVT trial, a randomized, double-blind study comparing once-daily fondaparinux (Arixtra®) with the low-molecular-weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep-vein thrombosis (DVT)
|
| The Matisse Investigators |
| |
|
The MATISSE-PE trial, a multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra®) with adjusted-dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE)
|
| The Matisse Investigators |
| |
|
The measurement and prevalence of antibodies to prothrombin in patients screened for anti-phospholipid syndrome
|
| Brookfield C., Moran R., Hampton K. K. |
| |
|
The mechanism of action of high-dose factor VIIa in preventing bleeding in hemophilia. Computational simulation studies
|
| Panteleev M.A., Ovanesov M.V., Ataullakhanov F.I. |
| |
|
The mechanism of platelet activation by recombinant factor VIIa in normal subjects and inherited hemostatic disorders – a whole blood, flow cytometric study
|
| Wilbourn B. R., Mackie I. J., Harrison P., Liesner R., Khair K., Machin S. J. |
| |
|
The mechanism of platelet aggregation in whole blood in response to adenosine triphosphate: involvement of neutrophil ecto-ATPase activity and adenosine
|
| Heptinstall S., Stafford N., White A. E. W., Glenn J. R. |
| |
|
The modulation of lipopolysaccharide induced gene expression and protein production by anti-thrombin
|
| Iampietro R., Romisch J., Gray E. |
| |
|
The molecular background to von Willebrand disease type 1 in Sweden
|
| Lanke E., Hall L., Hallden C., Johansson A., Hillarp A., Lethagen S. |
| |
|
The molecular basis of Glanzmann thrombasthenia in Arabs
|
| Rosenberg N., Peretz H., Usher S., Kenet G., Coller B. S., Awidi A., Seligsohn U. |
| |
|
The molecular basis of thrombin allostery revealed by a 1.8-Å structure of the ‘slow’ form
|
| Huntington J., Esmon C. T. |
| |
|
The molecular mechanisms of platelet activation by prolactin
|
| Kobsar A., Hild E., Wallaschofski H., Sokolova O., Lohmann T., Eigenthaler M. |
| |
|
The mutation Ser2117Leu, in the second hydrophobic spike of the factor V C2 domain, increases phospholipid affinity and specific activity
|
| Gilbert G. E., Kaufman R. J., Price P., Miao H., Pipe S. |
| |
|
The natural anticoagulant Thrombomodulin has radical scavenging activity and acts as an antioxidant C-type lectin
|
| Maruyama I., Yamaji K., Kawahara K., Sarker K. P., Iino S., Yamakuchi M., Stern D. M., Abeyama K. |
| |
|
The Nijmegen low-titer factor VIII inhibitor assay: a highly sensitive assay for the detection of low-titer factor VIII inhibitors
|
| Verbruggen B., Van Heerde W. L., Lourenssen G., Mensink E., Novakova I. R. O. |
| |
|
The omega-loop within the Gla domain (G4–Q11) and the EGF2 domain (C88–C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets
|
| Yang X., Walsh P. N. |
| |
|
The optimal duration of treatment with vitamin K antagonists in patients with a first episode of venous thromboembolism: a decision analytic approach
|
| Van Dongen C. J. J., Bossuyt P. M., Hutten B. A., Locadia M., Stalmeier P. F. M., Sprangers M. A. G., Middeldorp S., Bank I., Vink R., Büller H. R., Prins M. H. |
| |
|
The P2X1 receptor for ATP plays an essential role in platelet aggregation at high shear
|
| Cattaneo M., Marchese P., Jacobson K. A., Ruggeri Z. M. |
| |
|
The PAI-1 and tPA concentrations in patients with classic homocystinuria
|
| Castaneda S., Arbelaez L. F., Cordoba A. |
| |
|
The peptide LSARLAF causes platelet aggregation through PLCg2 and can induce platelet activation independent of GPIIbIIIa
|
| Pearce A. C., Wonerow P., Gartner T. K., Watson S. P. |
| |
|
The peptide LSARLAF directly induces a conformation change in the platelet integrin aIIbb3
|
| Taylor D., Derrick J. M., Cho M. J., Loudon R. G., Gartner T. K. |
| |
|
The PFA-100®: a screening tool for platelet dysfunction – the Oxford experience
|
| Sukhu K., Beavis J., Keeling D. M., Giangrande P. L. F., Harrison P. |
| |
|
The phagocytic capacity of human endothelial cells in culture for apoptotic endothelial cells is inhibited by IgG from patients with anti-phospholipid antibodies
|
| Morrison E. R., Graham A., Ford I., Erwig L. P., Greaves M., Barker R. N. |
| |
|
The platelet adhesion receptor, F11R (a.k.a. JAM-1), is critical for the initiation of plaque formation, thrombosis and atherosclerosis
|
| Kornecki E., Babinska A., Kedees M. H., Athar H., Sobocka M. B., Sobocki T., Ehrlich Y. H., Hussain M. M., Jiang X.-C. |
| |
|
The platelet ADP receptor P2Y12 is a critical player on the pathway of aIIbb3 activation by multiple agonists
|
| Delaney S. M., Jurek M., Vincent D., Manganello J., Conley P. B. |
| |
|
The platelet glycoprotein Ibalpha HPA-2 polymorphism affects VWF binding, but not thrombin interaction
|
| Ulrichts H., Vanhoorelbeke K., Cauwenberghs S., Vauterin S., Kroll B., Santoso S., Deckmyn H. |
| |
|
The platelet glycoprotein IIb/IIIa receptor antagonist c7E3Fab inhibits the coagualation activation in patients undergoing to percutaneous transluminal coronary angioplasty (PCTA)
|
| Musso R., Cultrera D., Sortino G., Azzaro M. P., Di Francesco E., Ferlito C., Giustolisi R. |
| |
|
The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction
|
| Grove E., Lassen J. F., Jensen H. K., Orntoft T. F., Kristensen S. D. |
| |
|
The possible role of calpain in cancer mediated vascular endothelial cell (vEC) retraction
|
| Tokunaga M., Ariyoshi H. A., Sakon M. S., Ueda A. U., Uchide K. U., Nakamura T. N., Monden M. M. |
| |
|
The predictive value of C-reactive protein (CRP) for myocardial infarction may be affected by aspirin therapy in men with lower extremity arterial disease
|
| MacCallum P. K., Cooper J. A., Price C., Meade T. W. |
| |
|
The predictors of clinical outcome in patients with heparin-induced thombocytopenia
|
| Kelton J., Hursting M. J., Lewis B. E. |
| |
|
The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma
|
| Van Heerde W., Reutelingsperger C. P. M., Maassen C., Lux P., Derksen R. H. W. M., De Groot P. G. |
| |
|
The prevalence and prognostic importance of elevated cardiac troponins in patients with acute submassive pulmonary embolism
|
| Douketis J., Johnston M., Leeuwenkamp O. R., Ten Wolde M., Sohne M., Buller H. |
| |
|
The prevalence of polymorphism PlA2 of platelet glycoprotein IIb-IIIa in the population of North-west Russia
|
| Panshina A. M., Shitikova A. S., Kapustin S. I., Blinov M. N. |
| |
|
The prevalence of, and molecular defects underlying, inherited Protein S deficiency in the general population
|
| Beauchamp N. J., Dykes A. C., Parikh N., Tait R. C., Daly M. E. |
| |
|
The principles of therapy of hemorrhagic vasculitis at children
|
| Plahuta T. G., Soskov G. I., Petrov V. Y., Lavrentieva N. N., Vdovin V. V., Gugeyedova O. A., Yatsenko E. A., Donush E. K. |
| |
|
The prion protein as a regulator of tPA activity
|
| Ellis V. |
| |
|
The prognostic value of platelet count drop in an intensive care unit
|
| Isvarlal P., Marinho A., Polo S., Lau C., Matos E., Brandão M., Campos M., Justiça B. |
| |
|
The protective effect of estradiol is dependent on immune system for spontaneous atherosclerosis but not for injury-induced atherosclerosis
|
| Delmas E., Gourdy P., Garmy-Susini B., Bayard F., Arnal J. F. |
| |
|
The prothrombinase enhancing activity exhibited by VLDL derived from patients with the biphasic APTT waveform is due to increased anionic phospholipid exposure
|
| Dennis M., Downey C., Nesheim M. E., Toh C. H. |
| |
|
The quality of care in the management of oral anti-coagulation therapy by the Belgian general practitioner
|
| Claes N., Buntinx F., Vijgen J., Arnout J., Vermylen J., Van Loon H. |
| |
|
The Rapidpoint™ ENOX point-of-care test has strong correlation with anti-Xa levels for detecting the anti-coagulant effects of enoxaparin
|
| Triscott M., Mahan D., De Anglis A., Leumas J., Mccallum S., Moliterno D. |
| |
|
The rate of thrombus resolution following treatment of DVT is related to the site and the precipitating cause of thrombosis
|
| Harper P., Young L., Mckelvie S., Rolfe-Vyson V., Shirley K., Ockelford P. |
| |
|
The regulation of thrombin formation by protein S in plasma in the absence of APC
|
| Seré K. M., Rosing J., Hackeng T. M. |
| |
|
The relation between clinical phenotype and genotype of severe hemophilia A
|
| Van Dijk K., Van Der Bom J. G., Ploos Van Amstel J. K., Fischer K., Mauser-Bunschoten E. P., Nieuwenhuis H. K., Zewald R. A., Van Den Berg H. M. |
| |
|
The relation of activated protein C resistance with ABO blood groups
|
| Ozcan M., Kasapoglu A., Topcuoglu P., Arslan O. |
| |
|
The relationship between acute ischemic stroke (AIS) per se and plasma D-D (D-D) levels
|
| Kelly J. A., Lewis R. R., Rudd A., Parmar K., Moody A., Hunt B. J. |
| |
|
The relationship between APTT and lupus anticoagulants
|
| Connor P., Parmar K., Hunt B. J. |
| |
|
The relationship between genetic variants in peroxisome proliferator-activated receptors and venous thromboembolism in African-Americans and Caucasians
|
| Hooper W. C., Austin H., Dowling N. F., Whitsett C., Evatt B. L., Benson J. |
| |
|
The relationship between nonenzymatic glycation and fibrin structure/function: a mechanism for increased vascular risk associated with hyperglycemia
|
| Dunn E., Ariens R. A. S., Grant P. J. |
| |
|
The relationship between plasma D-dimers (D-d) and thrombus load in patients with deep vein thrombosis (DVT) after acute ischaemic stroke (AIS): a prospective study using magnetic resonance direct thrombus imaging (MRDTI)
|
| Kelly J. A., Lewis R. R., Rudd A., Parmar K., Moody A., Hunt B. J. |
| |
|
The relationship between risk factors for premature vascular disease in systemic lupus erythematosis (SLE) with secondary anti-phospholipid syndrome (APS)
|
| Hampton K., Brookfield C., Sheli N., Akil M., Snaith M. |
| |
|
The relationship between sh-CRP and reactivity of monocytes and various blood parameters known to play an important role in atherogenesis
|
| Breimo E., Brox J., Elvevoll E. O., Eilertsen K. E., Lund T., Olsen J. O., Østerud B. |
| |
|
The relationship between the TNF-308 polymorphism and Legg-Perthes disease
|
| Hooper W. C., Dilley A., Pyle M., Eldridge J., El-Jamil M. |
| |
|
The relative importance of P2Y12/P2Y1 in thrombin/ADP-induced platelet activation and true synergistic action in-between inhibition of P2Y12 and P2Y1
|
| Nylander S., Mattsson C., Ramström S., Lindahl T. L. |
| |
|
The risk of heparin-induced thrombocytopenia and the frequency of heparin-dependent antibodies in neurologic patients treated with unfractionated heparin
|
| Harbrecht U., Bastians B., Kredteck A., Hanfland P., Klockgether T., Pohl C. |
| |
|
The risk of postoperative hemorrhage after intracranial surgery following early Nadroparin administration – results of a prospective study
|
| Gerlach R., Scheuer T., Böhm M., Raabe A., Scharrer I., Seifert V. |
| |
|
The risk of pregnancy complications in women from families with thrombophilic defects
|
| Middeldorp S., Bank I., Libourel E. J., Hamulyak K., Van Der Meer J., Koopman M. M. W., Van Pampus E. C. M., Prins M. H., Buller H. R. |
| |
|
The risk of recurrence after a first episode of venous thromboembolism in cancer patients
|
| Cosmi B., Legnani C., Cini M., Valdrè L., Coccheri S., Palareti G. |
| |
|
The risk of thromboembolism and the effectiveness of prophylactic treatment in thrombophilia patients undergoing major orthopaedic surgery: a systematic review
|
| Wu O., Robertson L., Langhorne P., Twaddle S., Lowe G., Clark P., Walker I., Brenkel I., Greaves M., Regan L., Greer I. |
| |
|
The role of herpetic infections in genesis of endothelial damage in pregnant women with fetal loss syndrome
|
| Dolgushina N., Makatsaria A. D. |
| |
|
The role of integrin alpha2beta1 during activation of protein tyrosine kinases induced by low concentration of collagen
|
| Kralisz U., Stasiak M., Cierniewski C. S. |
| |
|
The role of molecular markers of the coagulation system in patients with acute myocardial infarction
|
| Korzh O. |
| |
|
The role of platelet concentrate in the treatment of von Willebrand's disease
|
| Schlammadinger Á., Rázsó K., Pósán E., Boda Z., Pfliegler G. |
| |
|
The role of spiral CT in alternative diagnosis in patients with clinical suspicion of pulmonary embolism
|
| Huisman M. V., Van Strijen M. J. L., De Monye W., Kieft G. J. K., Pattynama P. M. T., Bloem H. L., Blanga J. D. |
| |
|
The role of TAFIa in relation to serpin inhibitors of fibrinolysis
|
| Mutch N. J., Moore N. R., Thomas L., Booth N. A. |
| |
|
The role of the ATP-Binding Cassette transporter A1 (ABCA1) in phosphatidylserine cell surface exposure and in the modulation of the procoagulant phenotype
|
| Proulle V., Hamon Y., Laude I., Leclerc P., Chimini G., Freyssinet J. M., Kerbiriou-Nabias D. |
| |
|
The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser-induced model of arterial thrombosis in vivo
|
| Lenain N., Freund M., Hechler B., Leon C., Evans R., Cazenave J-P., Gachet C. |
| |
|
The role of thrombophilia in the development of atherothrombosis in diabetes mellitus
|
| Popova L., Bokarev I. |
| |
|
The role of thrombophilias in the origin of cerebrovascular accidents at the patients with Atrial Fibrillation
|
| Bokarev I. N., Kozlova T. V., Patrushev L. I., Efimov V. S. |
| |
|
The role of tissue factor on the inhibition of prothrombin activation and thrombin generation by the synthetic pentasaccharide (fondaparinux)
|
| Gerotziafas G., Depasse F., Chakroun T., Van Dreden P., Elalamy I., Samama M. M. |
| |
|
The role of tissue factor on the inhibition of prothrombin activation and thrombin generation by the synthetic pentasaccharide (fondaparinux)
|
| Gerotzuafas G. T., Depasse F., Chakroun T., Van Dreden P., Elalamy I., Samama M. M. |
| |
|
The role of vascular endothelial growth factor in an early phases of proangiogenic changes in human endothelial cells
|
| Baranska P., Pawlowska Z., Jerczynska H., Cierniewski C. S. |
| |
|
The role of VWF in immune tolerance induction
|
| Kreuz W. |
| |
|
The roles of serum insulin-like growth factor and binding protein, human growth hormone, matrix metalloproteinases and interleukin-10 in coronary heart disease to heart failure
|
| Jong G., Ma T. |
| |
|
The safety and efficacy of beriplex P/N for rapid warfarin reversal in major hemorrhage – a prospective evaluation of a regional protocol
|
| Sharples R. |
| |
|
The safety profile of Argatroban in acute stroke: results of a prospective trial
|
| LaMonte M. |
| |
|
The scaffold function of b3 integrins regulates integrin signaling
|
| Shattil S., Buensuceso C., Calderwood D., De Virgilio M., Garcia Arias-Salgado E., Obergfell A., Tadokoro S., Ginsberg M. H. |
| |
|
The sensitivity and specificity of ADAMTS13 activity for primary thrombotic thrombocytopenic purpura
|
| Hulstein J. J. J., Rison C., Hene R., De Groot F., Romijin R., Fijnheer R. |
| |
|
The severely impaired thrombin generation in 5 patients with severe factor XI deficiency and inhibitors is corrected in vitro by recombinant factor VIIa
|
| Livnat T., Salomon O., Zivelin A., Seligsohn U. |
| |
|
The small GTP-binding protein Ral is involved in cAMP-mediated release of VWF from endothelial cells
|
| Rondaij M., Sellink E., Gijzen K., Ten Klooster J., Hordijk P., Van Mourik J., Voorberg J. |
| |
|
The sorting signal for von Willebrand factor (vWF) granular storage lies within the first 140 amino acids of the D2 domain of the VWF propeptide (VWFpp)
|
| Haberichter S. L., Fahs S. A., Jozwiak M. A., Retzlaff K. L., Montgomery R. R. |
| |
|
The stability of 11-dehydro thromboxane B2 levels in random urine samples
|
| Mcgrath J., Johnston M. |
| |
|
The strong incidence of acquired and inherited thrombophilia in recurrent first trimester fetal loss
|
| Ciampa A., Manzo A., Grandone E., Margaglione M., Volpe E. |
| |
|
The structural role of glycine-193 in serine proteases: active site investigations of Gly193Val mutant of factor IXa and crystal structure of factor VIIa/soluble tissue factor with a reversible inhibitor
|
| Schmidt A. E., Addison K., Schreuder H., Bajaj S. P. |
| |
|
The study on phenotype and genotype of Protein C in a Chinese family with hereditary Protein C deficiency
|
| Liu L., Guo W. R., Huang F. Q., Li J. Z., Schlelgel N. |
| |
|
The substitution of the factor Xa a-helix 345–352, which is a factor Va interactive site, by the corresponding structure of factor IXa does not affect formation and activity of the prothrombinase complex
|
| Thiec F., Cherel G., Christophe O. D. |
| |
|
The suitability of various evacuated blood collection tubes for monitoring heparin
|
| Munro R., Hardingham S., Dorward N., Morris K. |
| |
|
The synthetic retinoic acid receptor (RAR)-gamma agonist CD437 reduces procoagulant activity and induces apoptosis in breast cancer cells
|
| Balducci D., Marchetti M., Barbui T., Falanga A. |
| |
|
The test trombin for the whole blood (TTWB) is control of fibrinogen level for management of bleeding patient
|
| Katsadze Y. I. L. |
| |
|
The three I hemophilic study: a comparative study of the morbidity pattern between Asian Indian, Iranian and Italian PWH
|
| Shenoi J., Karimi M., Ross C., Chandramouli B., Santagostino E., Gringeri A., Mannucci P. M. |
| |
|
The thrombin generation test (TGT) may be a predictive parameter for thrombus formation during endovascular embolization of cerebral aneurysms
|
| Freyburger G., Berge J., Rakoto F., Labrouche S. |
| |
|
The thrombin potential in contrast to clotting times is only slightly modified after uncomplicated heart valve replacement in adults
|
| Carteaux J. P., Regnault V., Lekehal M., Lecompte T. |
| |
|
The thrombogenic agent in prothrombin complex concentrates (PCC): Identification of elevated levels of prothrombin as the major cause
|
| Hanker-Dusel C., Eich S., Grundmann C., Seitz R., König H. |
| |
|
The thrombotic risk of different types of oral contraceptives and interaction with factor V Leiden and the prothrombin 20210 A mutation: results of the MEGA study
|
| Van Hylckama Vlieg A., Doggen C. J. M., Rosendaal F. R. |
| |
|
The t-PA/PAI-1 complex in plasma in relation to risk of myocardial infarction as evaluated in the Stockholm heart epidemiological program (SHEEP)
|
| Sten-Linder M., Nordenhem A., Leander K., Hallqvist J., De Faire U., Wiman B. |
| |
|
The type 1/type 2M von Willebrand disease dilemma: findings from the Canadian Type 1 VWD study
|
| Notley C., Cameron C. L., James P. D., Hegadorn C. A., Rapson D. A., Benford K., Hough C., Hough Ahcdc, Lillicrap D. P. |
| |
|
The uremic retention solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair in vitro
|
| Dou L., Cerini C., Bertrand E., Faure V., Sampol J., Vanholder R., Berland Y., Brunet P. |
| |
|
The use of corn trypsin inhibitor to reduce the effect of sample contact activation in assays utilizing low tissue factor
|
| Luddington R., Langdown J., Baglin T. |
| |
|
The use of phospholipid-dependent clotting assays to characterize the cell-surface procoagulant activities of T-lymphoblastoid cell lines
|
| Pickering W., Gray E., Goodall A. H., Ran S., Thorpe P. E., Barrowcliff T. W. |
| |
|
The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome
|
| Chuansumrit A., Tangnararatchakit K., Lekakul Y., Pongthanapisith V., Nimjaroenniyom N., Thanarattanakorn P., Wongchanchailert M., Komwilaisak P. |
| |
|
The use of synthetic triple helical peptides to define a recognition motif in collagen III for human platelet receptor, Glycoprotein VI
|
| Farndale R., Andrews A., Knight C. G., Smethurst P. A., Ouwehand W. H. |
| |
|
The use of the rotational thrombelastograph (ROTEG) in the quantification of the ‘lytic state’ during thrombolytic therapy: a comparative analysis in the subhuman primate
|
| Franz R., Joubert J. E. H., Briedenhann S., Meintjes C. J., Jenner W. J., Silva L., Becker P. |
| |
|
The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy
|
| Rawle F. E. M., Brown B., Shi C. X., Mckinven A. J., Tinlin S., Shaw M., Hough C., Graham F., Lillicrap D. P. |
| |
|
The use of two plasma derived Factor VIII concentrates in type 2 A von Willebrand's disease (VWD)
|
| Morley N., Makris M., Hampton K. |
| |
|
The utilities of recalcification time clot wave-form in the evaluation of the hemostatic effect of factor VIIa in hemophilia A and B
|
| Shima M. |
| |
|
The Veterans Affairs Cooperative Studies Program's ‘80+ Hemorrhagic Cohort Study
|
| Brophy M.T., Cantillon C.E., Young M., Gagnon D.R., Fiore L.D. |
| |
|
Theoretical and experimental investigation of the D2194G subsitution in the C2 domain of coagulation factor V
|
| Villoutreix B. O., Miteva M. A., Brugge J. M., Nicolaes G. A. F. |
| |
|
Therapeutic monitoring of bleeding disorders: The RoTeg method
|
| Carr M. |
| |
|
There are no presentations related to this session
|
|
| |
|
There are no presentations related to this session
|
|
| |
|
There are no presentations related to this session
|
|
| |
|
There is no north/south gradient distribution of the plasma fibrinogen level and of the C-148T Fg genotype in a French native population (The Fitenat Study)
|
| Mazoyer E., Gueguen R., Tiret L., Varsat B., Ripoll L., Duchose G., Bal dit Sollier C., Drouet L. |
| |
|
Three abnormal patterns for inversion breaking intron 1 of the FVIII gene
|
| Vinciguerra C., Zawadsky C., Macchi L., Dargaud Y., Negrier C. |
| |
|
Three novel missense mutations in the b-propeller domains of GPIIb (aIIb integrin) among three unrelated patients with Glanzmann thrombasthenia from southern India
|
| Nelson E. J. R., Shaji R. V., Chandy M., Srivastava A. |
| |
|
Three novel point mutations that cause severe factor XI deficiency in two unrelated Japanese families
|
| Morishita E., Kuroda K., Ohtake S., Ontachi Y., Mizutani T., Yamazaki M., Asakura H., Nakao S. |
| |
|
Thrombin accelerates regeneration of mouse peripheral nerve in vivo
|
| Balezina O. P., Gerasimenko N. Y., Dugina T. A., Strukova S. M. |
| |
|
Thrombin activable fibrinolysis inhibitior (TAFI) in patients with obesity
|
| Kolacz E., Lewandowski K., Turowiecka Z., Kasprzak A., Zawilska K. |
| |
|
Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
|
| Antovic J., Yngen M., Östenson C. G., Antovic A., Wallen N. H., Jorneskog G., Blombäck M. |
| |
|
Thrombin activatable fibrinolysis inhibitor in thrombophilic patients with activated protein C resistance
|
| Ramsis N., Goubran F., Selim S. |
| |
|
Thrombin activates the cGMP-inhibited cAMP-dependent phosphodiesterase (PDE3A) in platelets
|
| Zhang W., Colman R. W. |
| |
|
Thrombin binding to GPIba induces platelet adhesion, aggregation and fibrin clot retraction supported by resting a Iibb 3 interaction with polymerized fibrin
|
| Dubois C., Steiner B., Meyer Reigner S. C. |
| |
|
Thrombin causes an inflammatory cytokine response, which is inhibited by protein C, in both primary human monocytes and a monocyte (THP-1) cell line
|
| Hodgson A., Hochart H., Murphy C. V., Livingstone W., Smith O. P. |
| |
|
Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS)
|
| Furie K., Thompson J. L. P., Bauer K. A., Rosenberg R., Mohr J. P., Rosner B., Sciacca R., Thornell B. J., Kelly P. J., Barzegar S., Lu Y., Kistler J. P. |
| |
|
Thrombin Generation Assay: Using Bedside Monitoring as a Dosage Guidance
|
| Negrier C. |
| |
|
Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hyper- or hypo-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma
|
| Chantarangkul V., Clerici M., Bressi C., Giesen P. L. A., Tripodi A. |
| |
|
Thrombin generation in clotting factor deficiency: mathematical model
|
| Khanin M., Rakov D. V. |
| |
|
Thrombin generation in patients with stroke and elevated factor VIII levels
|
| Klinge J., Kerschbaum G., Rauh M., Lischetzki G. |
| |
|
Thrombin generation in platelet-rich plasma (PRP) is enhanced in patients with metabolic syndrome
|
| Wegert W., Mahnel R., Bassus S., Jaursch-Hanke C., Kirchmaier C. M. |
| |
|
Thrombin generation in response to methionine loading test in patients with ischemic heart disease
|
| Domagala T., Undas A., Celinska-Lowenhoff M., Iwaniec T., Szczeklik A. |
| |
|
Thrombin generation in von Willebrand diseases
|
| Rugeri L., Bordet J. C., Dargaud Y., Negrier N. |
| |
|
Thrombin generation on the platelet surface
|
| Hoffman M. |
| |
|
Thrombin induces the expression of pro-MMP-2 and its conversion to MMP-2 in vascular smooth muscle cells: both responses are inhibited by red wine polyphenols
|
| Oak M. H., El Bedoui J., Schini-Kerth V. B. |
| |
|
Thrombin potential in heparin induced thrombocytopenia
|
| Davidson S. J., Burman J. F., Wadham P. |
| |
|
Thrombin receptors on the cells of the blood–brain barrier
|
| Bartha K., Vajda S., Kollár A., Machovich R., Adam V. |
| |
|
Thrombin regulates the expression of its cellular inhibitor protease nexin-1 in smooth muscle cells
|
| Richard B., Arocas V., Guillin M.C., Michel J.B., Jandrot-Perrus M., Bouton M.C. |
| |
|
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
|
| Bouma B. N., Meijers J. C. M. |
| |
|
Thrombin-activatable fibrinolysis inhibitor is not associated with the occurrence of ischemic stroke
|
| Lee Y. K., Kang H. J., Cho H. C., Lee B., Yu K. |
| |
|
Thrombin-blood coagulation factor XIII interaction: in silico experiments
|
| Komáromi I., Muszbek L. |
| |
|
Thrombin-induced platelet signaling results in factor IXa binding to a subpopulation of platelets with low or absent GP1b antigen
|
| London F. S., Marcinkiewicz M., Walsh P. N. |
| |
|
Thrombin-mediated Ca2+ responses in chick embryo cardiomyocytes and cardiofibroblasts
|
| Strukova S., Ide J., Aoki T., Glusa E., Ishiwata S. |
| |
|
Thrombinography can differentiate bleeding from nonbleeding patients with prolonged APTT
|
| Regnault V., Briquel M. E., Nguyen P., Laurian Y., Béguin S., Hemker H. C., Lecompte T. |
| |
|
Thrombocyte retraction does not strength blood clot
|
| Savushkin A. V. |
| |
|
Thrombocytopenia in HIV-infected patients, a report from HIV/AIDS Counseling and Care Center in Kermanshah, Iran
|
| Alaei K., Alaei A., Davood M., Shaban A. |
| |
|
Thromboembolism in childhood: a prospective 2 years study in the United Kingdom (February 2001 – February 2003)
|
| Gibson B. E. S., Chalmers E. A., Bolton-Maggs P., Henderson D. J., Lynn R. |
| |
|
Thrombolysis induced by streptokinase or recombinant plasminogen activator (rt-PA) is improved by SSR182289A, a direct orally active thrombin inhibitor, in rabbit models of thrombosis
|
| Visconte C., Lorrain J., Sainte-Marie M., Millet L., O'Connor S. E., Schaeffer P., Herbert J. M. |
| |
|
Thrombolytic action of longolytin – product of low fungi Arthrobotrys longa in rabbit thrombosis model
|
| Serebrjakova T. N., Sharkova T. S., Podorolskaya L. V., Neumivakin L. V., Andreenko G. V., Semionova N. A. |
| |
|
Thrombolytic effect of AT1 receptor antagonists – losartan and its metabolite EXP 3174 in rat
|
| Chabielska E., Nazarko J., Rozmyslowicz W., Mogielnicki A., Buczko W. |
| |
|
Thrombolytic properties of normal human neutrophils
|
| Chee Y. L., Moir E., Booth N. A., Greaves M., Bennett B. |
| |
|
Thrombolytic therapy in acute ischemic stroke: same method, same team, different drug
|
| Szegedi N., May Z., Ovary C., Skopal J., Harsanyi A., Nagy Z. |
| |
|
Thrombolytic therapy with tissue plasminogen activator (tPA), analysis of safety and outcome in children
|
| Browne M., Newall F., Campbell J., Savoia H. F., Monagle P. |
| |
|
Thrombomodulin regulates activity, localization and expression of nitric oxide synthase inhuman umbilical vein endothelial cells (HUVECs)
|
| Rendu F., Brunet A., Millanvoye Van Brussel E., David-Dufilho M. |
| |
|
Thrombophilia – from the roots to the base of evidence. Preliminary results on platelet function and rheologic parameters and the necessity of prospective multicentre cohort trials
|
| Schenk J. F., Ames M., Pindur G., Stephan B., Seyfert U. T. |
| |
|
Thrombophilia and pregnancy
|
| Papaioannou G., Speletas M., Chasapopoulou H., Kioumi A., Rafail S., Katodritou E., Korantzis I. |
| |
|
Thrombophilia and residual vein thrombosis are independent risk factors for recurrent venous thromboembolism
|
| Cosmi B., Legnani C., Cini M., Valdre L., Guazzaloca G., Coccheri S., Palareti G. |
| |
|
Thrombophilia does not increase the risk for neonatal complications in preterm infants
|
| Kenet G., Maayan A., Rosenberg N., Sella B. A., Quint J. |
| |
|
Thrombophilia in pregnancy, combined oral contraceptives and hormone replacement therapy users: a systematic review
|
| Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G., Walker I., Brenkel I., Greaves M., Regan L., Greer I. |
| |
|
Thrombophilia strikes at all ages
|
| Van Mierlo P. J. W. B., Kamphuisen P. W., Söhne M., Jacobs E. M. G., Ullmann E. F., Büller H. R. |
| |
|
Thrombophilic risk factors and idiopathic sudden sensorineural hearing loss
|
| Le Cam-Duchez V., Chorin S., Fretigny M., Dehesdin D., Levesque H., Borg J.-Y |
| |
|
Thrombophilic risk factors of ischemic stroke in children
|
| Raszeja-Specht A., Pilarska E., Bakowska A., Wróblewska M., Szutowicz A. |
| |
|
Thrombophilic screening in patients with paroxysmal nocturnal hemoglobinuria
|
| Dragoni F., Iori A. P., Avvisati G., Pignoloni P., Minotti C., Arcese W., Bernasconi S., Mazzucconi M. G. |
| |
|
Thrombophilic tendency in patients with chronic renal disease submitted to regular dialysis
|
| Sioulis A., Grekas D., Girtovitis F., Tasiopoulou K., Avdelidou A., Makris P. E. |
| |
|
Thrombopoeitin: a tool to understand thromobopoiesis
|
| Kaushansky K. |
| |
|
Thrombopoietin increases platelet adhesion and decreases rolling to von Willebrand factor
|
| Wu Y., Van Os E., Pouwels J. G., Van Willigen G., De Groot P. G., Akkerman J.-W. N. |
| |
|
Thromboprophylaxis in laparoscopic cholecystectomy: identification of a high-risk group of patients
|
| Volteas S., Sikiotis K. |
| |
|
Thromboprophylaxis in medical patients: national survey of consultant physicians in the United Kingdom
|
| Alikhan R., Wilmott R., Khan A., Cohen A. T. |
| |
|
Thromboprophylaxis in orthopedic surgery: Clinical practice in the Netherlands
|
| Nurmohamed M. T., Van Meeteren M., Schonenberg D., Nelissen R. G. H. H., Van Der Horst-Bruinsma I. E., Poll R. G. |
| |
|
Thrombosis do not recur at conventional dose oral anticoagulation (INR 2–3) in primary anti-phospholipid syndrome: comparison with inherited thrombophilia at similar INR
|
| Ames P. R. J., Ciampa A., Iannaccone I., Brancaccio V., Scenna G. |
| |
|
Thrombosis in Neonates and children at various sites (1999–2002): thrombophilic factors, recurrence and outcome
|
| Pergantou H., Kapsimalis Z., Adamtziki E., Platokouki H., Aronis S. |
| |
|
Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series
|
| Zelcer S., Bussel J. B. |
| |
|
Thrombosis prophylaxis following total hip replacement
|
| Caprini J. A., Kudrna J. C., Sehgal L. R., Martchev D., Maksimovic D., Glase C., Arcelus J. I. |
| |
|
Thrombosis risk factor assessment in surgical patients: compliance with chest consensus guidelines
|
| Caprini J. A., Glase C., Martchev D., Oyslender M., Arcelus J. I., Maksimovic D. |
| |
|
Thrombospondin triggers P-selectin expression and phosphatidyl serine exposure on platelets
|
| Le Courvoisier-Flaujac C., Adam F., Guillin M.C., Jandrot-Perrus M. |
| |
|
Thrombospondin-1 promotes transendothelial migration of monocytes associated with platelets
|
| Jurk K., Strey A., Janning A., Gerke V., Van Aken H., Kehrel B. E. |
| |
|
Thrombotic events associated with the use of recombinant factor VIIa in a single institution: a role for caution
|
| Ng H., Loh Y. S. M., Ho L. P., Tien S. L. |
| |
|
Thrombotic potential may be increased in healthy individuals with a two-generation family history of premature myocardial infarction
|
| Goodall A., Wright J. R., Bhatti A., Qamar N., Desouza P., Ogleby J., Singh R. K., Gray E., Samani N. J. |
| |
|
Thrombotic risk factors in stroke patients
|
| Ataç B., Özbek N., Can U., Verdi H., Benli S., Kýlýnç M., Çeliker G. |
| |
|
Thrombotic risk in first-degree relatives of factor V Leiden (FVL) and factor II G20210A carriers
|
| Oliveira L. C. O., Rizzatti E. G., Inácio R. A. S., Torrano-Masetti L., Baggio M. S., Tavella M. H., Franco R. F. |
| |
|
Thrombotic thrombocytopenic purpura in a patient with acquired vWF protease (ADAMTS13) deficiency was heralded by variable stimuli and lacked a good correlation between platelet counts and vWF protease levels
|
| Thompson P., Li Z. Y., Oton A. B., Morgensztern D., Lian E. C. |
| |
|
Thromboxane A2 is a weak platelet agonist requiring coactivation of both the P2Y1 and the P2Y12 receptors for full platelet activation to occur
|
| May J. A., Heptinstall S. |
| |
|
Time-dependent distribution of P-selectin in an arterial thrombus in vivo defines leukocyte rolling during thrombus formation
|
| Furie B., Gross P. L., Furie B. C. |
| |
|
Time-dependent restoration of effective inhibition of blood platelet function after coronary artery by-pass grafting
|
| Golanski J., Golanski R., Iwaszkiewicz A., Watala C. |
| |
|
Timing of initial administration of prophylaxis against deep vein thrombosis in patients following hip or knee surgery
|
| Hull R. D., Burke N., Mah A. F., Pineo G. F. |
| |
|
TIMP-1, TIMP-2 and MMP-9 as prognostic markers for clinical outcome in sepsis
|
| Hoffmann U., Brückmann M., Dvorsak E., Liebe V., Borggrefe M., Haase K. K., Huhle G. |
| |
|
Tissue factor (TF) and high-sensitivity CRP (HS-CRP) in patients with peripheral arterial disease (PAD) undergoing peripheral bypass surgery or angioplasty: a retrospective study
|
| Dörffler-Melly J., De Stoer W., Legemate D., Banyai S., Koppensteiner R., Koopmann M. M., Reitsma P. H., Büller H. R. |
| |
|
Tissue factor (TF) gene expression analysis in blood monocytes
|
| Mueller J., Rox J., Poetzsch B. |
| |
|
Tissue factor activity is controlled by its inhibitor and redox state: Findings in endothelial microparticles, monocytes, and a porcine trauma model
|
| Horstman L., Cast L., Jy W., Jimenez J. J., Ahn Y. S. |
| |
|
Tissue factor and tissue factor pathway inhibitor expression by adherent monocytes and alveolar macrophages
|
| Bajaj M. S., Kraus D., Carnaghi L., Kisiel W., Bajaj S. P. |
| |
|
Tissue factor and tissue factor pathway-inhibitor in chronic hepatitis C patients
|
| Goubran F., Abou El Ala A., El-Deib A., Basma El Din B. |
| |
|
Tissue factor de-encryption
|
| Bach R. |
| |
|
Tissue factor expression by human endothilial cells is down-regulated by antagonists of the renin-angiotensin system
|
| Napoleone E., Di Santo A., Donati M. B., Lorenzet R. |
| |
|
Tissue factor in sickle cell disease: Source and potential mediators
|
| Setty Y., Kulkarni S., Hevelow M., Key N. S., Stuart M. J. |
| |
|
Tissue factor is a major determinant of thrombogenicity following an acute myocardial infarction
|
| Grundt H., Nilsen D. W. T., Hetland O. |
| |
|
Tissue factor is present in platelet-derived microparticles from healthy donors
|
| Siddiqui F. A., Desai H., Amirkhosravi A., Siddiqui T. F., Meyer T., Amaya M., Ahmad S., Francis J. L. |
| |
|
Tissue factor itself is vital for the development of cell types with constitutive tissue factor expression but not for cell types without such expression
|
| Brüggemann L. W., Reitsma P. H., Spek C. A. |
| |
|
Tissue factor pathway in carotid atherosclerotic plaques: relationships with clinical patterns and risk factors
|
| Zawadzki C., Haulon S., Susen S., Vincentelli A., Jeanpierre E., Lucas C., Van Belle E., Richard F., Corseaux D., Jude B. |
| |
|
Tissue factor pathway inhibitor (TFPI)-mediated inhibitory effect of heparin on endothelial cell tube formation and angiogenesis-induced by FGF-2 or TF/VIIa
|
| Mousa S. |
| |
|
Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis
|
| Hamuro T., Kido H., Asada Y., Hatakeyama K., Okumura Y., Iwanaga S., Kamei S. |
| |
|
Tissue factor pathway inhibitor-2 (TFPI-2) binds the complement and kinin binding protein gC1qR/p33 (gC1qR)
|
| Peerschke E. I. B., Ruf W., Petrovan R. J., Miyagi Y., Ghebrehiwet B. |
| |
|
Tissue factor predicts long-term outcome after percutaneous coronary revascularization
|
| Susen S., Sautiere K., Zawadzki C., Bauters A., Dallongeville J., Asseman P., Bauters C., Lablanche J. M., Jude B., Van Belle E. |
| |
|
Tissue factor stimulates migration by activation of the mitogen-activated proteinkinase p38 and the GTPase Rac1
|
| Ott I., Michl R., Weigand B., Schömig A., Neumann F. J. |
| |
|
Tissue factor/factor Vlla interaction induces activation of the pro-inflammatory JAK/STAT pathway
|
| Versteeg H. |
| |
|
Tissue factor: lessons from knock-outs, knock-ins and transgenic mouse models
|
| Mackman N. |
| |
|
Tissue Factor-603 A–G promoter polymorphism is associated with human monocyte constitutive but not with LPS induced gene expression
|
| Reny J. L., Laurendeau I., Fontana P., Bieche I., Remones V., Emmerich J., Aiach M., Gaussem P. |
| |
|
Tissue factor-bearing microparticles arise from monocyte lipid rafts and can fuse with activated platelets, consolidating all of the membrane-bound coagulation reactions on the platelet surface
|
| Conde I., Shrimpton C. N., Thiagarajan P., Lopez J. A. |
| |
|
Tissue-specific regulation of protein S gene transcription
|
| De Wolf C. J. F., Bertina R. M., Vos H. L. |
| |
|
Tissue-type plasminogen activator (t-PA) gene deletion in apoE3-Leiden mice delays progression of cholesterol-induced atherosclerotic lesion
|
| Rezaee F., Gijbels M. J., Offerman E. H., Verheijen J. H. |
| |
|
Tissue-type plasminogen activator is a multiligand cross-b structure receptor
|
| Kranenburg O., Bouma B., Kroon-Batenburg L. M. W., Reijerkerk A., Wu Y-P., Voest E. E., Gebbink M. F. B. G. |
| |
|
Titer of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems
|
| Chilver-Stainer L., Lämmle B., Alberio L. |
| |
|
TNF-alpha promoter polymorphisms (-238 and -308) in patients with cerebrovascular disease
|
| De Oña R., Llamas P., Fernandez De Velasco J., Meseguer E., Escheverria A., Rábano J., Santos A., Soto C., Subirá D., Tomás J. F. |
| |
|
To evaluate the mechanism of neutrophil activation caused by a Cox-2 inhibitor-celecoxib
|
| Liao C. H., Hsiech Y. J., Lee T. U. |
| |
|
Total fibrin ‘super glue’ components from human plasma: a new blood banking procedure
|
| Shanbrom E., Owens E. |
| |
|
Total knee arthroplasty in hemophilic arthropathy
|
| Trieb K., Panotopoulos J. |
| |
|
Towards the development of a recombinant von Willebrand factor-cleaving protease (ADAMTS-13)
|
| Plaimauer B., Zimmermann K., Völkl D., Mohr G., Wernhart W., Antoine G., Schwarz H. P., Lämmle B., Scheiflinger F. |
| |
|
tPA as a modulator of neuronal function and survival
|
| Strickland S. |
| |
|
Tracking the uptake of evidence: two decades of hospital practice trends for diagnosing deep vein thrombosis and pulmonary embolism
|
| Stein P. D., Hull R. D., Ghali W. A., Patel K. C., Olson R. E., Meyers F. A., Kalra N. K. |
| |
|
Trafficking and cell surface dynamics of tissue factor pathway inhibitor in living cells
|
| Lupu F., Crawley J. T. B., Lupu C. |
| |
|
Transcription of plasminogen gene in mouse hepatocytes is regulated by cellular density
|
| Ueshima S., Akao M., Okada K., Seki T., Ariga T., Matsuo O. |
| |
|
Transcriptional silencing of TFPI-2 gene by hypermethylation of the promoter in choriocarcinoma cells
|
| Hubé F., Reverdiau P., Iochmann S., Rollin J., Cherpi-Antar C., Gruel Y. |
| |
|
Transdermal hormone replacement therapy does not affect hemostasis and inflammation
|
| Papa M. L., Capasso F., Pudore L., Torre S., Russo V., Vitale S., Albolino L., Papa R., Cerasuolo L., Tesorone M., Bartoli M. G., Insidioso M., De Lucia D. |
| |
|
Transfusion of activated platelets: increase of platelet-leukocyte binding in vivo
|
| Gutensohn K., Brockmann M. A., Geidel K., Kuehnl P. |
| |
|
Transgenic mice studies demonstrate a role for platelet factor 4 (PF4) in thrombosis: implications for heparin-induced thrombocytopenia (HIT)
|
| Eslin D. E., Zhang C., Samuels K. J., Gewirtz J. E., Cines D. B., Poncz M., Kowlaska M. A. |
| |
|
Transient lupus anti-coagulant directed against factor II
|
| Mathias M., Liesner R., Khair K., Hann I., Burgess C. |
| |
|
Transition of treatment with i.v. Argatroban to Phenprocoumon and Acencoumarol
|
| Harder S., Hentig N. V., Walenga J. M., Osakabe M., Watanabe H., Breddin H. K. |
| |
|
Translocation of plasma membrane Ca2+-ATPase to filopodia during platelet activation
|
| Dean W., Zabe M., Whiteheart S. W. |
| |
|
Transmembrane TNFa and wild-type TNFa differently modulate atherosclerotic process in mice
|
| Nalbone G., Canault M., Peiretti F., Mueller C., Kopp F., Morange P., Juhan-Vague I. |
| |
|
Transmission electron microscopy of granulocyte inclusions in genetically confirmed MYH9-related disorders
|
| Pujol-Moix N., Kelly M. J., Herández A., Muñiz-Diaz E., Salvadó J. M., Español I., Busqué A., Souto J. C., Soria J. M., Fontcuberta J. |
| |
|
Transport of blood samples through a pneumatic tube system causes loss of platelet function
|
| Ibberson J., Preece N., Brown P. R., Makris M., Kitchen S. |
| |
|
Treatment and management of women with bleeding disorders and menorrhagia (WBDM) study: study design and characteristics of women enrolled
|
| Miller C. H., Dilley A., Heit J. A., Kouides P. A., Philipp C. S., Stein S. F., Evatt B. |
| |
|
Treatment of acquired factor VIII inhibitor using Feiba and Prednisone
|
| Antunes M., Dominguez C., Nogueiras T., Sousa Mendes D., Marques C., Dias M., Diniz M. J. |
| |
|
Treatment of acute pulmonary embolism during pregnancy with low-molecular weight heparin
|
| Kaaja R., Ulander V.- M. |
| |
|
Treatment of adults with sepsis-induced coagulopathy and purpura fulminans with a plasma-derived protein C concentrate (Ceprotin®)
|
| Schellongowski P., Bauer E., Locker G., Frass M., Staudinger T., Knöbl P. |
| |
|
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy
|
| Kaaja R., Ulander V.-M. |
| |
|
Treatment of DIC: the role of PC
|
| Makris P. E., Girtovitis F., Papadopoulos A., Tamioulaki A., Kosmidou M., Pithara E. |
| |
|
Treatment of myelodysplastic syndrome with arsenic trioxide (ATO): response in refractory, transfusion-dependent patients
|
| Saba H., Morelli G. A., Loughran T. |
| |
|
Treatment of patients with a history of heparin-induced thrombocytopenia (HIT type II) and of anti-lepirudin antibodies with argatroban or lepirudin
|
| Harenberg J., Jorg I., Fenyvesi T., Osakabe M., Manning A. |
| |
|
Treatment of patients with inhibitors with FEIBA: the French experience from 1995 to 1999
|
| Goudemand J., Négrier C., Ounnoughène N., Torchet M. F., Lauroua P., Reynaud J. |
| |
|
Treatment of patients with VWD requiring elective surgery with a pasteurized von Willebrand Factor/FVIII concentrate (Haemate®P) – the use of a PK-guided approach
|
| Lethagen S. R., Kyrle P. A., Schulman S., Haertel S., Muysers C., Mannucci P. M. |
| |
|
Treatment of recurrent arterial thrombosis with hirudin in congenital afibrinogenaemia
|
| Schuepbach R., Meili E. O., Schneider E., Peter U., Bachli E. B. |
| |
|
Treatment of severe canine hemophilia A by helper-dependent adenoviral-mediated gene therapy
|
| Brown B., Shi C. X., Webster S., Tinlin S., Graham F., Lillicrap D. |
| |
|
Treatment of thrombotic complications and prophylactic use of protein C concentrate in two homozygous protein C deficient patients during surgery
|
| Hertfelder H. J., Kornbrust A. M., Pannier-Fischer M., Rabe E., Hanfland P., Lentze M. J. |
| |
|
Treatment with recombinant activated factor VII of intra-abdominal bleeding associated with disseminated intravascular coagulation caused by septic shock
|
| Cid A. R., Martínez J., Aznar J. A., Haya S., Moscardó F., Lorenzo J. I., Sanz M. A. |
| |
|
Trends in incidence and diagnosis of heparin-induced thrombocytopenia at a tertiary medical center
|
| Francis J., Drexler A. |
| |
|
Triatomine extrinsic pathway inhibitor (TEPI) from the blood sucking insect Dipetalogaster Maxima™
|
| Von Sicard N. |
| |
|
Triglycerides show an immediate increase during anticoagulant therapy for DVT without increase in thrombin generation
|
| Korte W., Zoller N., Corbetta C., Riesen W. |
| |
|
Triple heterozygosity in the alphaIIb gene of a patient with Glanzmann thrombasthenia and platelets with a low alphaIIbbeta3 content
|
| Nurden A. T., Breillat C., Bourre F., Lillicrap D., Rand M., Wang H., Blanchette V. S., Schmugge M. |
| |
|
Trp2063 and Trp2064 in the factor V C2 domain are required for factor Va binding to phospholipid membranes but not for assembly of the prothrombinase complex
|
| Peng W., Quinn-Allen M. A., Kim S. W., Kane W. H. |
| |
|
Two candidate type 2 M von Willebrand disease mutations in two unrelated families with unusual phenotypes
|
| Enayat M. S., Guilliatt A. M., Surdhar G. K., Williams C. E., Williams M. D., Hill F. G. H. |
| |
|
Two electrophoretic fibrinogen variants found in patients with normal coagulation and familial thrombosis
|
| Hanss M., Ffrench P., Mornex J. F., De Mazancourt P., Dechavanne M. |
| |
|
Two novel mutations in severe factor VII deficiency
|
| Gomez K., Laffan M. A., Kemball-Cook G., Pasi K. J., Layton M., Tuddenham E. G. D., Mcvey J. H. |
| |
|
Two sensitive chromogenic assays of fondaparinux sodium (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in plasma
|
| Paolucci F., Van Aarle F. G. B., Capdevila A., Clavies M. C., Donat F., Frasa W. L. H., Frasa W. L. H., Hendriks-Linders Y. E. M., Nadal T., Necciari J., Perez Y., Van Den Heuvel M. W., Van Dinther T. G. |
| |
|
Type 2 M von Willebrand disease due to linked P1266Q and V1279I substitutions in the von Willebrand factor A1 domain
|
| Kroner P. A., Friedman K. D., Valentino L. A., Czapek E. E., Wetzel N., Benziger L. B., Montgomery R. R. |
| |
|
Type 2M von Willebrand disease: correlation of phenotype with genotype?
|
| Gilligan O. M., Keeney S., Watson P., Hay C. R. M., Cumming A. |
| |
|
Type 2N von Willebrand disease due to compound heterozygosity for the frequent R854Q type 2N mutation and a new R763G mutation abolishing the cleavage of von Willebrand factor propeptide
|
| Hilbert L., Nurden P., Caron C., Fressinaud E., Meyer D., Mazurier C. |
| |
|
Type Vicenza Arg1205His mutation alone induces reduction in the level and survival of von Willebrand factor
|
| Casonato A., Cattini M. G., Soldera C., Marcato S., Padrini R., Girolami A. |
| |
|
Type-2 mutations within the A1 domain of Von Willebrand Factor: how protein conformation modulates binding to platelet membrane GPIba
|
| Meyer D., Mazurier C., Sadler J.E. |
| |
|
Tyr1956 and Leu1957 in the factor V C1-domain are required for high affinity binding of factor Va to phospholipid membranes
|
| Peng W., Quinn-Allen M. A., Saleh M., Kane W. H. |
| |
|
Tyrosine kinases regulate the activation of phosphatidylinositol 3-kinase in platelets stimulated by the PAR1-activating peptide
|
| Lassila R., Kroll M. H., Reséndiz J. C. |
| |
